| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | necitumumab (Portrazza®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 966 |
| Indication | In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2016 |
| NICE guidance | TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |